Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing
Authors:
- Janaina Pontes Batista CassoliJCJanaina Pontes Batista Cassoli
- Ítalo FernandesÍFÍtalo Fernandes
- Leonardo CarvalhoLCLeonardo Carvalho
- Milena FernandesMFMilena Fernandes
- Ana Fernanda CentroneACAna Fernanda Centrone
- Letícia TaniwakiLTLetícia Taniwaki
- Rita de Cássia LimaRLRita de Cássia Lima
- Uelson Donizeti Rocioli JuniorUJUelson Donizeti Rocioli Junior
- Igor Wanderley Reis DiasIDIgor Wanderley Reis Dias
- Patrícia TarantoPTPatrícia Taranto
- Juliana BealJBJuliana Beal
- Fernanda Teresa de LimaFLFernanda Teresa de Lima
Open Access
- 25 July 2024
- journal article
- case report
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (8) , 7976-7985
Abstract
HER2-Low is defined as low levels of HER2 expression, based on a score of 1+ on immunohistochemical (IHC) assay or as an IHC score of 2+ and negative results on in situ hybridization (ISH or FISH). They are a heterogeneous population of breast cancers that vary in prognosis and sensitivity to systemic treatments. The frequency and clinical characteristics of pathogenic germline variants (PGVs) in HER2-Low breast cancer (BC) patients is not defined. We analyzed results from patients with BC who underwent multi-gene panel testing (MGPT) (maximum 145 genes) between 2018–2019. We reclassified HER-2 status accordingly. Relationships between the variables of interest were assessed by adopting the proportional regression Cox models. Of a total of 167 BC patients who underwent MGPT, half were hormone-receptor-positive. The median age was 45 years. About two thirds of the patients were in the earlier stage of BC. A total of 57% of the cases were reclassified as HER-2-negative or -Low. PGVs were found in 19% of the patients overall, as follows: seven BRCA1, four BRCA2, two ATM, one ATR, two CFTR, three CHEK2, one FANCA, one MERTK, one MLH1, three MUTYH, one RAD50, three RAD51C, one RECQL4, and two TP53 mutations. In HER2-Low, 26.5% of the patients had PGVs, and in the overall cohort, this was 19.8%. In conclusion, differences in the prevalence of deleterious germline mutations in HER2-Low BC patients compared to non-HER2-Low BC patients were identified. Similar alterations in BRCA were observed in this group of patients compared to the overall cohort. Germline genetic tests should be evaluated in larger cohorts of patients with HER2-Low status to better address the findings.Keywords
This publication has 30 references indexed in Scilit:
- Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeJAMA Oncology, 2021
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancernpj Breast Cancer, 2021
- Breast Cancer TreatmentJAMA, 2019
- Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium CohortJAMA Internal Medicine, 2018
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studiesThe Lancet Oncology, 2012
- Translational advances regarding hereditary breast cancer syndromesJournal of Surgical Oncology, 2012
- Molecular portraits of breast cancer: tumour subtypes as distinct disease entitiesEuropean Journal of Cancer, 2004
- Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States)Cancer Causes & Control, 2002
- Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the diseaseThe Lancet, 2001